Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
Rhea-AI Summary
Organovo Holdings (ONVO), a clinical stage biotechnology company focused on inflammatory bowel disease (IBD) treatments, has announced the issuance of 2,967,144 additional shares of common stock through warrant exercises and at-the-market sales.
The share issuance, registered under statements effective May 8, 2024, is expected to generate gross proceeds of approximately $2.3 million, before deducting fees and commissions. Following this issuance, Organovo's total outstanding common stock has reached 20,421,617 shares.
Positive
- Raised $2.3M in gross proceeds through warrant exercises and stock sales
- Successfully executed registered warrant exercises indicating investor participation
Negative
- Dilution of existing shareholders with 2.97M new shares issued
- Proceeds subject to reduction from fees and commissions
News Market Reaction – ONVO
On the day this news was published, ONVO declined 3.81%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact
CORE IR
pr@coreir.com
Source: Organovo, Inc.
FAQ
How many new shares did Organovo (ONVO) issue in March 2025?
How much money did Organovo (ONVO) raise from the March 2025 warrant exercises?
What is the total number of outstanding shares for Organovo (ONVO) after the March 2025 issuance?
When was the registration statement for Organovo's (ONVO) warrant exercises declared effective?
